Regeneron Pharmaceuticals Inc. buy melinda
Summary
This prediction ended on 02.08.18 with a price of €354.31. The prediction had a final performance of 13.53%. melinda has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 8.074% | 8.074% | 30.470% | 121.127% |
| iShares Core DAX® | 2.831% | 1.236% | 14.788% | 17.647% |
| iShares Nasdaq 100 | 2.918% | 0.640% | 40.290% | 50.762% |
| iShares Nikkei 225® | 2.007% | -2.135% | 19.861% | 4.937% |
| iShares S&P 500 | 2.257% | 0.451% | 30.090% | 43.940% |
According to melinda what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?
Pros
Cons
Comments by melinda for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Biotechnologie und medizinische SecteurRecherche
10. März (Reuters) - Regeneron Pharmaceuticals Inc. und Sanofi SA sagte am Samstag würden sie bereit sein , weniger für ihre potenten Wirkstoff aufzuladen gegen Cholesterin, Praluent, wenn die Versicherer vereinbaren teure Zugangsbarrieren für Patienten zu verringern hohe Risiko.
Da Zulassungen Praluent 2015 und andere biotechnologisch hergestelltes Medikament Rivalen Amgen Inc., Versicherer und Apotheken haben rund 70% der Verschreibungen gefüllt, stark behindert Umsatz und frustrierend Ärzte und Herzpatienten gefährdet abgelehnt.
Stopped prediction by melinda for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
09.11.21
09.11.22
10.11.22
Regeneron Pharmaceuticals Inc.
11.02.20
04.11.21
05.11.21
Regeneron Pharmaceuticals Inc.
02.12.18
11.01.19
11.01.19
Regeneron Pharmaceuticals Inc.
09.09.17
26.12.17
26.12.17
Regeneron Pharmaceuticals Inc.
09.09.17
26.12.17
26.12.17
Regeneron Pharmaceuticals Inc.
15.03.16
08.08.16
08.08.16
Regeneron Pharmaceuticals Inc.
01.07.13
01.01.14
01.01.14
Regeneron Pharmaceuticals Inc.
07.01.11
07.07.11
07.07.11